Literature DB >> 1778212

Radionuclide therapy of the thyroid.

S E Clarke1.   

Abstract

Radionuclide therapy has a proven place in the management of patients with thyroid disease. Iodine-131 therapy has been established as both successful and safe in treating patients with thyrotoxicosis and thyroid malignancy. Protocols for patient treatment are now standardised, although some variation in practice exists across Europe. There remains much confusion as to which patients should be selected for treatment with radio-iodine for thyrotoxicosis and what dose should be administered. A review of the literature reveals that many of the theoretical hazards of treatment with radio-iodine have not been encountered despite many years of usage. New therapies for medullary thyroid cancer are now being evaluated and recent promising developments are discussed in detail.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1778212     DOI: 10.1007/bf00180421

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  46 in total

1.  Leukaemia following radioiodine treatment of thyrotoxicosis.

Authors:  E E POCHIN
Journal:  Br Med J       Date:  1960-11-26

2.  Effect of pretreatment with methylthiouracil on results of I-131 therapy.

Authors:  J CROOKS; W W BUCHANAN; E J WAYNE; E MACDONALD
Journal:  Br Med J       Date:  1960-01-16

3.  Radioiodine I-31 therapy in the management of thyroid cancer. A prospective study.

Authors:  G T Krishnamurthy; W H Blahd
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

4.  Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the Cooperative Thyrotoxicosis Therapy Follow-Up Study.

Authors:  E L Saenger; G E Thoma; E A Tompkins
Journal:  JAMA       Date:  1968-09-16       Impact factor: 56.272

5.  Observations on the course of exophthalmos after 131-I therapy.

Authors:  D I Jones; D S Munro; G M Wilson
Journal:  Proc R Soc Med       Date:  1969-01

6.  Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants.

Authors:  E Arad; K Flannery; G A Wilson; R E O'Mara
Journal:  Clin Nucl Med       Date:  1990-10       Impact factor: 7.794

7.  Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma.

Authors:  L Von Moll; A J McEwan; B Shapiro; J C Sisson; M D Gross; R Lloyd; E Beals; W H Beierwaltes; N W Thompson
Journal:  J Nucl Med       Date:  1987-06       Impact factor: 10.057

8.  Nonimmunogenic hyperthyroidism: cumulative hypothyroidism incidence after radioiodine and surgical treatment.

Authors:  J A Kinser; H Roesler; T Furrer; D Grütter; H Zimmermann
Journal:  J Nucl Med       Date:  1989-12       Impact factor: 10.057

9.  Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism.

Authors:  J S Robertson; C A Gorman
Journal:  J Nucl Med       Date:  1976-09       Impact factor: 10.057

10.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.

Authors:  H R Maxon; S R Thomas; V S Hertzberg; J G Kereiakes; I W Chen; M I Sperling; E L Saenger
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.